Neumora Therapeutics (NMRA) Non-Current Debt (2025 - 2026)

Name: Neumora Therapeutics (NMRA) Non-Current Debt (2025 - 2026) | Business Quant
Creator: Business Quant

Neumora Therapeutics' quarterly Non-Current Debt came in at $53.0 million in Q1 2026, down 2.88% quarter-over-quarter from $54.5 million in Q4 2025.

Neumora Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $53.0 million in Q1 2026.

For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $53.0 million; the trailing twelve-month figure through Mar 2026 stood at $53.0 million (changed N/A YoY), and the FY2025 full-year result was $54.5 million, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $53.0 million, down from $54.5 million in the prior quarter.
The five-year high for Non-Current Debt was $54.5 million in Q4 2025, with the low at $19.5 million in Q2 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	319.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	105.94 Mn
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	-
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	1.99 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Neumora Therapeutics	328.27 Mn	328.27 Mn	-	52.96 Mn

Download Data 🔒